RxDoctor Payments Data

Annette Hoo

Optometrist · Bridgeport, CTNPI 1285783670

Payments from drug & device makers

$3,520in general payments, 2019–2025

Across 159 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$1K
  • Alcon$465
  • Novartis$432
  • Bausch & Lomb Americas Inc.$373
  • Oyster Point Pharma, Inc.$242
  • AbbVie$226
  • plus $525 from 9 others

What the payments were for

  • Food & beverage$3,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,520 in reported general payments places this provider in the 85th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,120
Medicare patients
112
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine139$160,017
XiidraLifitegrast78$114,754
CequaCyclosporine14$23,229
RocklatanNetarsudil Mesylat/Latanoprost54$18,449
LumiganBimatoprost49$18,380
VyzultaLatanoprostene Bunod50$15,914
Cyclosporine25$9,674
Travoprost103$9,357
Azelastine Hcl160$3,527
Latanoprost520$3,398
SimbrinzaBrinzolamide/Brimonidine Tart12$2,524
Loteprednol Etabonate14$2,302
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$1,677
Prednisolone Acetate15$483
Timolol Maleate65$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$226$178,397188 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$373$130,668128 claims
Sun Pharmaceutical Industries Inc.Cequa$1,256$23,22914 claims
Aerie Pharmaceuticals, Inc.Rocklatan$23$18,44954 claims
AlconSimbrinza$465$2,52412 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$57$2,30214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 574 optometrist providers in Connecticut.

Other optometrist in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →